Preclinical Development Strategies for Novel Gene Therapeutic Products

Abstract

With over 220 investigational new drug applications currently active, gene therapy represents one of the fastest growing areas in biotherapeutic research. Initially conceived for replacing defective genes in diseases such as cystic fibrosis or inborn errors of metabolism with genes encoding the normal, or wild-type, gene product, gene therapy has expanded into other novel applications such as treatment of cancer or cardiovascular disease, where the risk: benefit profiles may be more acceptable in relation to the severity of the disease. Different types of vectors, including modified retroviruses, adenoviruses, adenovirus-associated viruses, and herpesviruses and plasmid DNA, are used to transfer foreign genetic material into patients' cells or tissues. Developing a toxicology program to determine the safety of these agents, therefore, requires a modified approach that encompasses the pharmacology and toxicity of both the gene product itself and the vector system used for delivery in the context of the application for the clinical trial. In general, the issues involved in designing and developing appropriate preclinical testing to determine the safety of these products are similar to those encountered for other recombinant molecules, including protein biotherapeutics. Limitations to some of the typical toxicology studies conducted for a traditional drug development program may exist for these agents, and nontraditional approaches may be required to demonstrate their safety. Many factors may affect the safety and clinical activity of these agents, including the route, frequency, and duration of exposure and the type of vector employed. Other safety considerations include quantitation of the duration and degree of expression of the vector in target and other tissues, the effects of gene expression on organ pathology and/or histology, evaluation of trafficking of gene-transduced cells or vector after injection, and interactions of the host immune system with the transduced cell population. Because of the unique concerns regarding each of these therapies, the Center for Biologics Evaluation and Research encourages sponsors to obtain toxicity data whenever possible while evaluating the pharmacologic activity of the vector in a species or animal model relevant to their clinical indication. Sponsors are encouraged to discuss preclinical study design and results with the Center during product development to facilitate early identification of safety concerns prior to entry of these novel agents into the clinical setting and to ensure an uninterrupted course of development while addressing issues required for licensure.

Keywords

Animal studies adenovirus plasmid DNA vector genetic disease

References

Food and Drug Administration, Center for Biologics Evaluation and Research (1991). Points to consider in human somatic cell therapy and gene therapy. Available at: http://www.fda.gov/cber.

Food and Drug Administration, Center for Biologics Evaluation and Research (December 1996). Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Fed. Register 61: 68269. Available at: http://www.fda.gov/cber .

Food and Drug Administration, Center for Biologics Evaluation and Research (March 1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy. Available at: http://www.fda.gov/cber.

National Institutes of Health, Office of Recombinant DNA Activities (May 1998). Quarterly report on human gene transfer protocols. Available at: http://www.nih.gov/od/orda/protocol.htm .